Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Tobias Welte (Hannover, Germany). Do we have any alternative therapeutic option beyond antibiotics?. Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions

Member's Comments

No comment yet.

Related content which might interest you: Which therapeutic options when CPAP fails?  Source: ERS Course 2017 - Paediatric noninvasive ventilation Year: 2017 Do we need new antibiotics? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009 The MABA approach: a new option to improve bronchodilator therapy Source: Eur Respir J 2013; 42: 885-887 Year: 2013 Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021 Year: 2021 Which patients with COPD can potentially benefit from prophylactic use of antibiotics? Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Second- and third-line therapies: what are the best options? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Antimicrobial resistance and new therapeutic options Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era Year: 2021 Inhaled antibiotics: a new tool? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009 Halotherapy and Covid-19: an oppinion for a possible future prevention approach Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021 Meta-analysis may not be practicable for guiding antibiotic therapy Source: Eur Respir J 2008; 31: 906-907 Year: 2008 Surgery as the best option in the multimodal treatment Source: Annual Congress 2013 –The management of N2 disease in non-small cell lung cancer Year: 2013 Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios Source: Eur Respir J 2015; 45: 25-29 Year: 2015 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016